
|Videos|September 24, 2021
Dr. Gao on treating re-emerged PARPi-resistant prostate cancer
Author(s)Urology Times staff
“Some potential…combination therapy may be valuable, such as combining with a checkpoint inhibitor or some target senescence because this resistance involves those kinds of mechanisms,” says Allen C. Gao, MD, PhD.
Advertisement
In this video, Allen C. Gao, MD, PhD, discusses the possibility of re-emerged PARP inhibitor resistant prostate cancer and what future studies should do to continue developing treatments. Gao was the senior author on the study, “
Gao is the Ralph de Vere White professor in the department of urologic surgery and director of urologic research at University of California, Davis.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA approves cefepime and zidebactam for complicated UTI
4
FDA updates in urology: May 2026
5











